Therefore, we believe that EZH2 can inhibit glioma migration by regulating the expression of SLC12A5, and the mechanism underlying this phenomenon is likely due to the activation of the WNK1-OSR1-NKCC1 cascade. The gene discussed is SLC12A2; the disease is central nervous system cancer.